Boston Scientific Corporation
BSX
$106.13
-$0.26-0.24%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 18.49B | 17.55B | 16.75B | 15.91B | 15.23B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 18.49B | 17.55B | 16.75B | 15.91B | 15.23B |
| Cost of Revenue | 5.91B | 5.54B | 5.29B | 4.97B | 4.77B |
| Gross Profit | 12.58B | 12.02B | 11.46B | 10.94B | 10.46B |
| SG&A Expenses | 6.49B | 6.22B | 5.98B | 5.75B | 5.43B |
| Depreciation & Amortization | 874.00M | 862.00M | 857.00M | 840.00M | 843.00M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.11B | 14.31B | 13.75B | 13.08B | 12.51B |
| Operating Income | 3.39B | 3.24B | 3.00B | 2.83B | 2.72B |
| Income Before Tax | 3.00B | 2.48B | 2.28B | 2.20B | 2.14B |
| Income Tax Expenses | 502.00M | 454.00M | 436.00M | 414.00M | 319.00M |
| Earnings from Continuing Operations | 2.50K | 2.03K | 1.85K | 1.79K | 1.83K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 8.00M | 8.00M | 7.00M | 4.00M | 4.00M |
| Net Income | 2.51B | 2.03B | 1.85B | 1.79B | 1.83B |
| EBIT | 3.39B | 3.24B | 3.00B | 2.83B | 2.72B |
| EBITDA | 4.70B | 4.53B | 4.27B | 4.06B | 3.95B |
| EPS Basic | 1.70 | 1.38 | 1.26 | 1.22 | 1.25 |
| Normalized Basic EPS | 1.50 | 1.27 | 1.18 | 1.10 | 1.05 |
| EPS Diluted | 1.68 | 1.37 | 1.25 | 1.21 | 1.23 |
| Normalized Diluted EPS | 1.49 | 1.25 | 1.16 | 1.09 | 1.04 |
| Average Basic Shares Outstanding | 5.90B | 5.89B | 5.89B | 5.88B | 5.87B |
| Average Diluted Shares Outstanding | 5.96B | 5.95B | 5.94B | 5.93B | 5.92B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | 0.00% | 0.00% |